Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director
~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~
Fennec Pharmaceuticals Inc, a leading biopharmaceutical company focused on the development of innovative oncology treatments, has recently announced the appointment of Jeffrey S. Hackman as its new Chief Executive Officer (CEO) and Director. With a strong track record in the pharmaceutical industry, Hackman’s extensive commercialization and oncology expertise positions him well to lead Fennec Pharmaceuticals into its next phase of growth and success.
Hackman brings over 20 years of experience in the pharmaceutical industry, with a deep understanding of drug development, regulatory affairs, and commercialization strategies. He has held various executive positions in renowned companies within the healthcare sector, including Bristol Myers Squibb, Eli Lilly, and Merck & Co. His proven leadership qualities have driven significant revenue growth and successful product launches, making him an ideal choice to guide Fennec Pharmaceuticals towards achieving its goals.
One of Hackman’s primary responsibilities as CEO will be to streamline the company’s commercialization strategies, ensuring enhanced market penetration for its innovative oncology treatments. Fennec Pharmaceuticals currently focuses on novel therapies for the treatment of pediatric cancers, with its lead product candidate, PedmarkTM, in late-stage clinical development for the prevention of ototoxicity induced by cisplatin chemotherapy in children.
Hackman’s expertise in the oncology space will be instrumental in accelerating the development and commercialization of PedmarkTM, while also exploring potential expansion opportunities into other cancer indications. His experience in navigating regulatory processes will also prove invaluable in securing necessary approvals and ensuring compliance with global regulatory standards.
Fennec Pharmaceuticals Inc recorded a cumulative net loss of $-13 million during the 12-month period ending in the fourth quarter of 2023, resulting in a negative return on assets (ROA) of -61.91%. Hackman’s appointment as CEO brings renewed hope and optimism for the company’s financial performance, as his extensive industry knowledge and proven success in commercializing pharmaceutical products are likely to drive the revenue growth necessary to strengthen the company’s financial position.
Comments